FINANCIAL INSTRUMENTS - Narrative (Details) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Nov. 19, 2021 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) customer	Dec. 31, 2020 USD ($) customer	Dec. 31, 2019 USD ($)	Jan. 31, 2022 USD ($)
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Additional liability payable to holders of CVRs				$ 989	$ (5,204)	$ (16,672)
Interest receivable		$ 100		100	1,600
Payments to acquire convertible note				611,488	546,516	318,484
Loss on equity investments				2,600
Payments to acquire investments				$ 17,187	$ 1,160	1,622
Number of major customers | customer				4	3
Contingent Consideration
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Gain related to acquisition				$ (989)
Spine BioPharma, LLC
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Convertible note paid for investment			$ 3,000
TELA Bio
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Equity investments					$ 11,600
Proceeds from sale of equity investment				9,100
Payments to acquire investments				1,600
Impairment loss					(5,700)
GeneQuine
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Equity investments		4,100		4,100
Investments fair value					$ 1,200
Payments to acquire convertible note				1,200
Investments in additional equity securities				3,000
Reduction in convertible note, due to foreign currency exchange rates				100
Potential additional investment upon achieving milestones		1,700		1,700
Coda BioTherapeutics, Inc
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Payments to acquire investments			$ 10,000
Genascence Corporation | Subsequent Event
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Equity investments							$ 7,500
Carrying Value
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Acquisition-related contingent consideration		57,598		57,598
Equity investments		14,127		$ 14,127
Major customer one | Accounts receivable | Credit risk
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Concentration risk (as a percent)				30.00%	36.00%
Major customer two | Accounts receivable | Credit risk
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Concentration risk (as a percent)				20.00%	28.00%
Major customer three | Accounts receivable | Credit risk
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Concentration risk (as a percent)				17.00%	23.00%
Major customer four | Accounts receivable | Credit risk
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Concentration risk (as a percent)				11.00%
Myoscience Acquisition
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Additional liability payable to holders of CVRs				$ (2,163)	$ 5,204	$ 16,672
Potential remaining milestone payments		$ 43,000		$ 43,000
Myoscience Acquisition | Level 3 | Weighted Average | Contingent Consideration | Discount rates
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Contingent consideration, liability, measurement input		0.118		0.118
Myoscience Acquisition | Level 3 | Weighted Average | Contingent Consideration | Probability of achieving regulatory milestones
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Contingent consideration, liability, measurement input		0.01		0.01
Flexion Acquisition
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Additional liability payable to holders of CVRs	$ (45,200)	$ (1,200)
Potential remaining milestone payments		$ 425,500		$ 425,500
Flexion Acquisition | Contingent Consideration
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Increase in CVR | $ / shares	$ 0.02
Flexion Acquisition | Level 3 | Weighted Average | Contingent Consideration | Discount rates
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Contingent consideration, liability, measurement input		0.122		0.122
Flexion Acquisition | Level 3 | Weighted Average | Contingent Consideration | Probability of achieving regulatory milestones
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Contingent consideration, liability, measurement input		0.127		0.127
Flexion and Myoscience Acquisition
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Acquisition-related contingent consideration		$ 57,600		$ 57,600	$ 28,300